Tarsus Pharmaceuticals Competitors and Similar CompaniesClear all
Tarsus Pharmaceuticals's competitors and similar companies include Biogen and Ipsen.
 Tarsus Pharmaceuticals Tarsus Pharmaceuticals is a biopharmaceutical company focused on the development of therapeutic candidates to address large market opportunities initially in ophthalmic conditions. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. | ||
Founding Date | Founding Date 2017 | Founding Date 1978 | Founding Date 1929 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Irvine, US HQ Irvine, US | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more |
Employees | Employees 32332% increase | Employees 7,605 | Employees 5,358 |
Valuation ($) | Valuation ($) 1.7 b | Valuation ($) 26.7 b | Valuation ($) 10.2 b |
Financial | |||
Revenue (est.) | Revenue (est.) $451.4m (FY, 2025) | Revenue (est.) $9.9b (FY, 2025) | Revenue (est.) €3.7b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $2.4b (FY, 2025) | Cost of goods €659.1m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $7.5b (FY, 2025) | Gross profit €3.3b (FY, 2025) |
Net income | Net income ($66.4m) (FY, 2025) | Net income $1.3b (FY, 2025) | Net income €445.1m (FY, 2025) |
Operating ⚠ | |||
Phase III Trials Products | Phase III Trials Products 1 (Q2, 2020) | Phase III Trials Products 11 (FY, 2024) | Phase III Trials Products N/A |
For sources of this data, please see the company profile
View Company Profiles
Biogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View company